- Details
- Alicia Morgans discusses the role of integrating patients in treatment decisions by incorporating quality of life, in particular when there are multiple treatments available with similar efficacy. Dr. Morgans emphasizes how patients should be included in the conversations and the decisions on treatment selection and considerations on efficacy, safety, and potential toxicities. She reiterates that...
|
- Details
- Michael Morris joins Alicia Morgans for a conversation on the focus of the GU Committee of the Alliance Cooperative Group that is led by Michael Morris. While there is a continued focus on advanced prostate cancer, there is an expected readout on a 12-year study in early disease, the CALGB 90203. CALGB 90203 (Alliance) looked at radical prostatectomy (RP) with or without neoadjuvant chemohormonal...
|
- Details
- Elena Castro, MD discusses her recent publication in Journal Clinical Oncology on DNA repair defects in prostate cancer. The primary objective of the study was to determine whether mutations in BRCA 1, BRCA 2, ATM and PALB 2 would affect survival in patients diagnosed with mCRPC. A panel of 107 genes was analyzed. Patients who were carrying these mutations, in particular, BRCA2, had shorter surviv...
|
- Details
- Bruce Montgomery shares an update on the PCF - VA research Initiative on precision oncology in prostate cancer. Prostate Cancer Foundation has provided a $50 million dollar contribution to this VA specific prostate cancer effort. Bruce and Chuck Ryan discuss the developments to date and the future plans. Biographies: Bruce Montgomery, MD Board-certified oncologist, clinical director of Genitourina...
|
- Details
- Charles Ryan, MD, and Fred Saad, MD have a clinical discussion on the full spectrum of castration-resistant prostate cancer (CRPC) from inception in both symptomatic vs asymptomatic patients from the evolution of abiraterone acetate and enzalutamide to the time point of integrating therapies earlier into CRPC. Dr. Saad discusses the development of prostate cancer and the optimal way for clinicians...
|
- Details
- Colleagues, Jaime Landman and Zhamshid Okhunov discuss office-based, ultrasound-guided renal mass biopsy. Jaime details the simplicity of this technique, the best candidate for this procedure, and the value in doing a renal biopsy with this technique. Biographies: Jaime Landman, MD Professor and Chairman, UCI Department of Urology, UC Irvine Medical Center Zhamshid Okhunov, MD, Urology Fellow, Dep...
|
- Details
- Leanne Schimke begins her presentation discussing the role of the nurse practitioner in the treatment of patients with advanced prostate cancer. She first looks at newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) patients. Also, presented is treatment options for mHSPC and the administration, adverse effects, nursing considerations, and drug interactions of these treatments. Bi...
|
- Details
- Scott Tagawa discusses his recent research on the use of antibody-drug conjugate (ADC) sacituzumab govitecan in advanced metastatic urothelial carcinoma. The primary endpoint of the study was the objective response rate and the results of the Phase 2 subset were presented at ASCO GU 2019. The responses were seen with reasonable drug tolerance, a manageable and predictable safety profile, and a rel...
|
- Details
- Alicia Morgans invites Tia Higano to discuss data analysis amongst patients with mCRPC who were enrolled in the Flatiron Health prostate cancer registry from 2013-2017. Findings include the discovery that 77% of patients receive some form of life-prolonging therapy and that only 60% of the patients ever received either denosumab or zoledronic acid. Alicia and Tia conclude by stating the importance...
|
- Details
- Stephen Williams and his team explored the question, what is the association of patient survival and intensity of treatment with total Medicare costs that are associated with radical cystectomy vs trimodal therapy for older adults with localized muscle-invasive bladder cancer in a time frame of longer than 180-days? He and Alicia Morgans discuss the study, its findings, and implications in patient...
|
